154 related articles for article (PubMed ID: 34916394)
1. Paradigm shift from palliation to cure in metastatic microsatellite high colorectal carcinoma with immune checkpoint inhibitors.
Dhamani AM; Sheth HS; Bhattacharyya S; Shaikh IN
J Cancer Res Ther; 2021; 17(6):1552-1555. PubMed ID: 34916394
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Das S; Allen A; Berlin J
Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
[TBL] [Abstract][Full Text] [Related]
3. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Gbolahan O; Hashemi-Sadraei N; O'Neil B
J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
[TBL] [Abstract][Full Text] [Related]
4. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
5. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
Liu N; Shan F; Ma M
Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
[TBL] [Abstract][Full Text] [Related]
6. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
7. Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Popov IP; Milicevic M; Kecmanovic D; Tomasevic Z; Radosevic-Jelic Lj; Borojevic N; Micev MT; Kezic I
J Exp Clin Cancer Res; 2006 Sep; 25(3):313-9. PubMed ID: 17167970
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
[TBL] [Abstract][Full Text] [Related]
10. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
[No Abstract] [Full Text] [Related]
11. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Afonso S; Viani G; Afonso V; Stefano E; Afonso S
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
[TBL] [Abstract][Full Text] [Related]
12. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
13. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Tozkir H; Albayrak D; Uzunoglu S; Cicin I
Hepatogastroenterology; 2015 Jun; 62(140):876-9. PubMed ID: 26902020
[TBL] [Abstract][Full Text] [Related]
14. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
[TBL] [Abstract][Full Text] [Related]
15. An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
Rizzo A; Palloni A; Frega G; Abbati F; De Lorenzo S; Brocchi S; Brandi G
Anticancer Drugs; 2019 Apr; 30(4):428-430. PubMed ID: 30875350
[TBL] [Abstract][Full Text] [Related]
16. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
17. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Del Rio M; Mollevi C; Bibeau F; Vie N; Selves J; Emile JF; Roger P; Gongora C; Robert J; Tubiana-Mathieu N; Ychou M; Martineau P
Eur J Cancer; 2017 May; 76():68-75. PubMed ID: 28284171
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for colorectal cancers].
Lièvre A; Mitry E
J Chir (Paris); 2003 Feb; 140(1):52-5. PubMed ID: 12709655
[TBL] [Abstract][Full Text] [Related]
20. Role of microsatellite instability in the management of colorectal cancers.
Buecher B; Cacheux W; Rouleau E; Dieumegard B; Mitry E; Lièvre A
Dig Liver Dis; 2013 Jun; 45(6):441-9. PubMed ID: 23195666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
